An Open Label Safety Study to Evaluate the Safety of Tipranavir Plus Ritonavir When Used in Combination With Other Agents for the Treatment of Patients With HIV Infection Who Have Failed and/or Are Intolerant to Combination Antiretroviral Therapy and Have Limited Treatment Options
- NCT00062660
- Not Specified
- EXPANDED_ACCESS
Last updated: 2016-11-30
Purpose of Trial
To provide early access to tipranavir and evaluate the safety and tolerance of tipranavir combined with low dose of ritonavir in patients with progressive, HIV-1 disease who have failed or are intolerant to currently approved treatments for HIV infection, who are unable to participate in another tipranavir controlled clinical trial and have an urgent need for anti-HIV treatment.
This study is for people with
HIV Infections
Interventions being studied
Tipranavir
Inclusion criteria:
Patients aho have a positive serology HIV antibody test confirmed by Western blot, p24 antigen assay, HIV-1 RNA or HIV culture and are highly pre-treated and virus resistant to multiple protease inhibitors.
ELIGIBILITY
Gender: ALL
Age: 2+
Healthy Volunteers: No
35 Locations
Scottsdale
1182.58.31
Arizona, United States
Los Angeles
1182.58.29
California, United States
Los Angeles
1182.58.34 Campus Code 696446
California, United States
Los Angeles
1182.58.42 Synergy Hematology/Oncology
California, United States
Los Angeles
1182.58.43
California, United States
San Francisco
1182.58.03
California, United States
San Francisco
1182.58.33 Kaiser Permanente Medical Center, Clinical Trials Unit
California, United States
Los Angeles
1182.58.37 AIDS Health Care Foundation
Connecticut, United States
Norwalk
1182.58.41 Circle Medical, LLC
Connecticut, United States
Washington
1182.58.28
District of Columbia, United States
Miami Beach
1182.58.38
Florida, United States
South Miami
1182.58.40 Drs. Raben and Feldman Research Associates
Florida, United States
Tampa
1182.58.23 Hillsborough County Health Department
Florida, United States
Atlanta
1182.58.36 Suite 525
Georgia, United States
Honolulu
1182.58.08
Hawaii, United States
Chicago
1182.58.22
Illinois, United States
New Orleans
1182.58.32
Louisiana, United States
Boston
1182.58.15
Massachusetts, United States
Detroit
1182.58.19 Henry Ford Hospital
Michigan, United States
Kansas City
1182.58.04 Kansas City Free Health Clinic
Missouri, United States
St. Louis
1182.58.25 Wohl Clinic
Missouri, United States
Las Vegas
1182.58.02 Wellness Center
Nevada, United States
New York
1182.58.09 Polari Medical Group
New York, United States
Chapel Hill
1182.58.30
North Carolina, United States
Cincinnati
1182.58.06 University of Cincinnati Medical Center, Infectious diseases
Ohio, United States
Portland
1182.58.35
Oregon, United States
Philadelphia
1182.58.14
Pennsylvania, United States
Pittsburgh
1182.58.20 University of Pittsburgh
Pennsylvania, United States
Columbia
1182.58.01 Boehringer Ingelheim Investigational Site
South Carolina, United States
Nashville
1182.58.10 Comprehensive Care Center
Tennessee, United States
Dallas
1182.58.18 University of Texas Southwest Medical Center at Dallas
Texas, United States
Houston
1182.58.07
Texas, United States
San Antonio
1182.58.039 Olmos Park Medical Associates
Texas, United States
Seattle
1182.58.11 Swedish Medical Center
Washington, United States
Madison
1182.58.44 VW Hospital and Clinics
Wisconsin, United States
Primary Contact(s)
Boehringer Ingelheim
Data obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Learn more at
ClinicalTrials.gov
